Medicine and Dentistry
Uterine Cancer
100%
Krukenberg Tumor
74%
Gynecological Oncology
61%
Recurrent Disease
57%
Ovarian Cancer
56%
Neoplasm
51%
Diseases
44%
CA-125
37%
In Vitro Fertilisation
36%
Cervical Cancer
28%
Overall Survival
28%
Carcinosarcoma
25%
Embryo Transfer
25%
Ovarian Tumor
24%
Hysterectomy
23%
Prognostic Factor
22%
Endometrium Carcinoma
22%
Follitropin
21%
Cervix
21%
Radiation Therapy
21%
Pelvis
19%
Placebo
19%
Niraparib
19%
Lymph Node
18%
Primary Peritoneal Carcinoma
18%
Carcinoma
17%
Diphtheria Toxin
16%
Recurrence Free Survival
16%
Cancer
16%
Polycystic Ovary Syndrome
16%
Progression Free Survival
16%
Ovulation Induction
15%
Retrospective Study
15%
Pregnancy Rate
15%
Adjuvant Therapy
14%
Adverse Event
14%
Oncology
14%
Topotecan
14%
Pharmacokinetics
14%
Human Menopausal Gonadotropin
14%
Hysteroscopy
14%
Cytoreductive Surgery
14%
Platelet
13%
Gonadotropin
12%
Long Term Survival
11%
Thrombocytosis
11%
Disease Specific Survival
11%
Maintenance Therapy
11%
Laparotomy
11%
Minimal Residual Disease
11%
Keyphrases
Endometrial Cancer
77%
Group Studies
57%
Gynecologic Oncology Group
57%
Israeli
54%
Primary Peritoneal Cancer
42%
Epithelial Ovarian Cancer
41%
Ovarian Cancer
31%
In Vitro Fertilization
31%
Overall Survival
27%
Israel
27%
Cervical Cancer
25%
CA-125 Levels
24%
ENGOT
24%
Ovarian Cancer Patients
24%
Hysterectomy
24%
Ovulation Induction
24%
Uterine Carcinosarcoma
23%
Pharmacokinetics
23%
Tumor
23%
Phase II Study
23%
Follicle-stimulating Hormone
22%
Advanced Ovarian Cancer
22%
Polycystic Ovary Syndrome
22%
Cancer Patients
19%
Endometrial Carcinoma
19%
Carbohydrate Antigen 125 (CA125)
19%
Niraparib
19%
Operative
17%
Diphtheria Toxin
16%
Gonadotropin-releasing Hormone
16%
Platinum Resistance
16%
Cervical Intraepithelial Neoplasia
15%
In Vitro Embryo Production
15%
Early-stage Cervical Cancer
15%
Prognostic Factors
15%
Placebo
15%
Patient Survival
14%
Laparotomy
14%
Chemotherapy
14%
Weekly Topotecan
14%
Carboplatin
14%
Paclitaxel
14%
Embryo Transfer
14%
Prognostic Significance
14%
PRIMA
14%
Platinum Sensitivity
14%
Epithelial Ovarian Carcinoma
13%
Tubal Carcinoma
13%
Gonadotropins
13%
Human Menopausal Gonadotropin
13%